Press Release Details
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
15th Annual
Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemia
Presenter:
Session: Poster
Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia
Presenter:
Session: Poster
Type: Fireside Chat Presentation
Date/Time:
TIDES
Title: Novel TRiM™ Platform for Oligonucleotide Delivery to Trabecular Meshwork via Local
Date/Time:
Presenter:
Session: Oligonucleotide Discovery, Preclinical and Clinical
Title: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)
Date/Time:
Presenter:
Session: Featured Science: Novel Approaches to Managing Lipid Risk
Title: Plozasiran and Triglyceride Levels in Hypertriglyceridemia: Long-Term Efficacy and Safety Data from Subjects in an Open-Label Extension Trial (MUIR and SHASTA-2 OLE)
Date/Time:
Presenter:
Session: New Insights in Lipids and lipid lowering therapies
The Liver Meeting 2024 -
Title: Long-Term Safety and Efficacy of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Enrolled in the Phase 2 Placebo-Controlled SEQUOIA Trial
Date/Time:
Presenter:
Session: Metabolic and Genetic Disease
Title: Digital Image Quantification of Collagen Proportionate Area Correlates with METAVIR Fibrosis Stage and Liver Stiffness Measurement Via FibroScan® in Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Date/Time:
Presenter:
Session: Metabolic and Genetic Disease
Title: Concordance of Histological and Liquid Chromatography Mass Spectrometry-Based Intrahepatic Z-Alpha-1 Antitrypsin (Z-AAT) Burden Assessments in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Date/Time:
Presenter:
Session: Metabolic and Genetic Disease
Type: Fireside Chat Presentation
Date/Time:
Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
About
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104447357/en/
626-304-3400
ir@arrowheadpharma.com
Investors:
212-915-2578
britchie@lifesciadvisors.com
Media:
724-910-9389
kguarinoni@lifescicomms.com
Source: